BRAF and thyroid cancer: Sorafenib is a tyrosine kinase inhibitor being used in advanced iodine-refractory thyroid cancer and is known to inhibit BRAF kinase phosphorylation in the MAPK pathway [25]; of note is the fact that sorafenib also inhibits CMV replication [24].